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Prion protein-mediated disorders appear to originate 
from the aggregation reactions of the prion protein. 
Like other amyloidogenic proteins, prion proteins 
form a range of fibrillar morphologies. The pre-
fibrillar forms seen at the beginning of the reaction 
are also heterogeneous; hence it appears that struc-
tural heterogeneity sets in early during the aggrega-
tion reaction. The prion protein aggregation may 
therefore proceed from many different precursor 
states, and structural heterogeneity in prion fibrils 
might originate from the utilization of distinct nuclea-
tion and elongation mechanisms. This review discusses 
the current understanding of the structural heteroge-
neity inherent in the aggregation reactions of prion 
proteins. It examines how an understanding of the 
structural and mechanistic basis of prion protein  
aggregation can provide molecular-level insights into 
the characteristic features of prion disorders, namely 
the infectious nature of the prion protein, prion strain 
phenomena and species barriers. 
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THE prion protein (PrP) is a highly conserved glycopro-
tein, which is expressed ubiquitously in the mammalian 
brain, specifically in neurons1–3. It is composed of  
two domains4, is anchored to the cell membrane through 
a C-terminal glycophosphatidylinositol (GPI) anchor,  
and is also glycosylated at two asparagine residues. The 
N-terminal domain is largely disordered, and has  
4–5 octa-peptide repeats (Figure 1 a). It has a high affin-
ity for divalent metal ions, such as Cu2+, and becomes 
partially structured upon interaction with Cu2+ (refs 5–7). 
The C-terminal portion is structured, consists of  
three long α-helices and two small β-strands, and has  
a disulphide bond that links helices 2 and 3 (Figure 1 a 
and b). 
 The exact biological function of the prion protein is 
unknown. It has, however, been linked to multiple physio-
logical processes8,9. An alternative, non-native conforma-
tion of the prion protein, PrPSc, is infectious, and causes 
prion diseases10,11, a group of fatal neurodegenerative 
diseases, which include Creutzfeldt-Jakob disease (CJD), 
fatal familial insomnia (FFI), mad cow disease and 
scrapie. 
Discovery of the prion 
The cause of CJD was unknown for many years. The  
disease was known to progress fast, after onset, causing 
death within a few months without invoking any immune 
response12–14. Similarities between CJD and Kuru in  
humans15, and also between Kuru in humans and scrapie 
in sheep16, became evident. Upon vaccination of sheep 
against scrapie, using a formalin-treated suspension of 
ovine brain and spleen, the sheep, instead of developing 
immunity against scrapie, succumbed to the disease17, 
suggesting that the pathogen is resistant to formalin and 
heat. It was proposed that scrapie is caused by a ‘slow  
 
 
 
 
 
Figure 1. Schematic of the full length mammalian prion protein (PrP) 
and NMR structure of C-terminal folded domain of PrP. a, Primary 
structure of the cellular prion protein (PrPC). The full length mammal-
ian prion protein has 209 amino acid residues, and consists of two do-
mains. The N-terminal domain (23–120) is unstructured and contains 
4–5 octapeptide repeats, shown in blue boxes between residues 51 and 
91. The C-terminal domain (121–231) is folded into two small  
β-strands and three α-helices. This protein is anchored to the cell 
membrane by a glycosylphosphatidylinositol (GPI) anchor at the C-
terminus. There are two glycosylation sites, at residues 181 and 197. A 
disulphide bond links α-helix 2 to α-helix 3. b, NMR structure of the 
folded C-terminal domain (residues 121–231) of the recombinant hu-
man prion protein. The disulphide bond linking α-helix 2 to α-helix 3 
is shown in yellow. The structure has been drawn from the PDB entry 
1QM3, using PyMOL (http://www.pymol.org). 
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virus’18. Along similar lines, it was proposed that Kuru  
is also transmissible like scrapie, and also occurs because 
of a ‘slow virus’16,19. It was later shown that the  
scrapie agent is highly resistant to ionizing and UV radia-
tions20–22. A similar resistance was seen for the CJD 
agent23. These findings led to the conclusion that the 
agents causing these diseases possessed highly unusual 
properties. 
 The nature of the infectious agent was highly debated. 
Ideas regarding its nature ranged from it being a small 
DNA virus or a membrane fragment, to a polysaccharide 
or a protein24–30. It was observed that procedures that 
modified or hydrolysed proteins (such as treatment with 
sodium dodecyl sulphate (SDS), urea, guanidinium thio-
cyanate or phenol) affected the infectivity, whereas  
procedures that modified nucleic acids did not10,31–33. The 
results established, for the first time, that a protein was 
required or responsible for these unusual diseases. The 
infectious agent was named as prion (‘proteinaceous  
infectious particle’)10. 
 After it was established that the infectious agent is a 
protein, efforts were directed towards discovering the 
identity and properties of this protein. It was observed 
that a purified sample, which was enriched in scrapie  
infectivity, contained mostly one protein34,35, which 
showed remarkable resistance to protease cleavage. Re-
sistance to proteinase K cleavage helped in the isolation 
of a protein fragment of an apparent molecular weight of 
27–30 kDa, which was called PrP 27–30 (refs 36 and 37). 
The resistance to proteolysis hindered sequence determi-
nation of this protein36. However, sequencing of its  
N-terminal region led to the subsequent molecular clon-
ing of the PrP gene1,2. It was realized that PrP 27–30 is 
the N-terminally truncated part (residues ~ 89–231) of the 
full-length prion protein1,2. 
 Interestingly, PrP was detected at similar levels in 
crude lysates of scrapie-infected brain and in normal 
brain37, supporting the hypothesis that PrP might be a 
secondary component involved in the disease38. It was, 
however, seen that the structural properties of the protein 
were different in the uninfected and diseased animals, 
which suggested that the normal (cellular) form of the 
prion protein (PrPC) adopts an alternative conformation 
(PrPSc) in prion diseases39. 
 There has been much debate about whether prion dis-
eases occur through the novel alternative conformation of 
the protein, or not. Evidence supporting the ‘protein only 
hypothesis’ is that the prion protein is required for patho-
genesis, as mice lacking the prion protein never develop 
prion diseases40,41. It has also been observed that overex-
pression of the prion protein causes a decrease in the in-
cubation period (the duration between infection and 
appearance of disease symptoms) of prion diseases, as 
well as an increase in susceptibility, suggesting that the 
protein is important for prion pathogenesis42. Further-
more, in the presence of lipid and RNA, full length  
recombinant moPrP converts in vitro into an infectious 
isoform43. Upon intra-cerebral injection into mice  
expressing the normal level of prion protein, they develop 
disease with all the neuropathological hallmarks of prion 
diseases43. These observations confirm that no genetic 
material is required for prion transmission. The conver-
sion of PrPC into its pathogenic isoform is facilitated by 
RNA (polyanions) and lipid, which can also be achieved 
just by changing the physical nature of the reaction con-
ditions44. 
The PrPSc conformation and prion-mediated  
toxicity 
The nature of PrPSc is still poorly defined, but it forms an 
aggregate, which shares features of amyloid fibrils 
formed by many other proteins. Amyloid fibrils are pro-
tein aggregates with a high internal order. They possess a 
characteristic cross-β motif, a β-sheet bilayer, in which 
the sheet is organized parallel to and the β-strands per-
pendicular to the fibril axis45,46. The formation of amyloid 
fibrils by specific proteins is associated with specific neu-
rodegenerative disorders47,48. Like amyloid fibrils, the 
PrPSc conformation of the prion protein is β-rich49, and is 
thermodynamically more stable50, more resistant against 
protease digestion34–37 and less soluble than its normal 
cellular counterpart, PrPC. Furthermore, prion rods, seen 
during the purification of PrPSc from the diseased brain, 
display properties of amyloid fibrils51. The amyloid 
plaques, formed in prion diseases, are rich in prion pro-
tein52–54. Thus, it seems that PrPSc represents either amy-
loid fibrils of the prion protein, or amyloid aggregates 
formed during the course of amyloid fibril formation by 
the prion protein. 
 Although the formation of PrPSc is often associated 
with prion diseases, the molecular mechanism of prion-
mediated toxicity is unclear. Mice lacking PrPC are nor-
mal, and resistant to prion disorders40,41, suggesting that 
the loss of PrPC function due to its conversion into PrPSc 
is not the cause of the disease. Grafting PrPSc into a brain 
region lacking PrPC does not lead to prion pathogenesis55, 
suggesting that PrPSc is not toxic by itself. More recently, 
it was shown that depleting PrPC prevents disease and  
reverses spongiosis56,57, suggesting that there is a constant 
requirement of PrPC for pathogenesis. Furthermore, prion 
pathogenesis does not show a correlation with the amount 
of PrPSc and sometimes the disease occurs even in the  
absence of any detectable PrPSc, suggesting again that 
PrPSc may not be the toxic form58–63. 
 In the case of amyloid-related diseases, a view has 
emerged that the final amyloid fibrils are not the toxic 
form. Instead, the intermediate oligomers and protofibrils 
formed along the pathway of fibrillation appear to be the 
toxic forms48,64–66. Along similar lines, it is possible  
that during the process of conversion of PrPC to PrPSc,
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Figure 2. Structural models of prion aggregates. a, Uranyl acetate-stained two-dimensional crystals of nanogold-labelled PrP 27–
30. The high contrast of the uranyl stain has obscured some of the labels. However, a few are clearly visible (arrowheads). Reprinted 
with permission from Wille et al.74. b, Two-dimensional crystals of PrP 106, stained with uranyl acetate. The scale bars in panels 
(a) and (b) represent 100 nm. Reprinted with permission from Wille et al.74. c, A top-down view of the left-handed β-helical model 
(reprinted with permission from Govaerts et al.75). d, The spiral model of protease-resistant PrP. Reprinted with permission from 
DeMacro and Daggett76. e, Parallel in-register structure of the amyloid fibrils formed by the C-terminal domain of PrP. Reprinted 
with permission from Cobb et al.82. 
 
 
intermediate oligomeric states, which are toxic, accumu-
late. Indeed, it has been reported that an oligomer is the 
most infectious species in prion disorders67. The oli-
gomeric forms found at the initial times of prion aggrega-
tion appear to be toxic68. But mature amyloid fibrils 
formed by the prion protein have also been reported to 
show toxicity68, as do mature fibrils formed by other pro-
teins69. It seems that fibril fragmentation enhances the  
cytotoxicity associated with amyloid fibrils69, but it re-
mains to be seen whether fibril fragmentation increases 
the amount of toxic oligomeric intermediates of the prion 
protein as well as of other amyloidogenic proteins. 
Structural studies on PrPSc-like conformations 
and regions involved in PrPC to PrPSc transition 
While a high-resolution structure of PrPC is available70, 
not only is the structure of PrPSc ill-defined, but so also is 
its size, because of its high heterogeneity and insolubility. 
No covalent modification has been shown to be required 
for PrPSc formation71,72. Fourier-transform infrared 
(FTIR) spectroscopy of PrPSc shows a β-rich structure49; 
in contrast, PrPC is α-rich. Epitope mapping also shows 
that PrPC and PrPSc have different structures73. Further-
more, PrPSc has higher thermodynamic stability50, and,  
as noted above, a greater resistance to protease diges-
tion34–37. 
 Multiple models have been proposed for the structure 
of PrPSc. Electron crystallography of the two-dimensional 
crystals of PrP 27–30 (described above; Figure 2 a) and a 
mini-prion, PrPSc106 (Δ23–88, Δ141–176; Figure 2 b)74 
has suggested a model (Figure 2 c) in which residues 89–
175 form left-handed β-helices and the C-terminal region 
remains in the native-like conformation75. 
 Some molecular dynamic simulation studies have sug-
gested that the core of amyloid protofibrils of the prion 
protein is composed of three-stranded sheets containing 
residues 116–119, 119–132 and 160–164 and an isolated 
strand containing residues 135–140 (ref. 76). The growth 
of protofibrils appears to occur via association of identical 
interfaces in which the isolated fourth strand is connected 
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to the three-stranded sheet forming a continuous four-
stranded sheet, where the first and fourth strand interface 
forms spiral protofibrils with a 31 axis of symmetry (spi-
ral model; Figure 2 d). According to this model, the three 
helices of the native protein are mostly unaffected or in-
tact in protofibrils76. This model was also found to be 
consistent with the 2D crystal of PrPSc (Figure 2 a). An 
experimental assessment of the β-helical and spiral model 
has suggested that the spiral model for PrPSc (Figure 2 d) 
is consistent with most of the biochemical characteristics 
of the PrPSc conformation77. An important result of these 
studies is that the α-helices of the C-terminal domain re-
tain their structure, and do not participate in the conver-
sion of PrPC to PrPSc. 
 On the other hand, a comparison of several features of 
the structure of PrPC to structures in a databank of  
‘normal’ proteins has suggested that the most unusual 
structural features of PrPC are found in helix 2 (residues 
172–194), which appears to be energetically frustrated in 
its helical state78. Molecular dynamics simulations sug-
gest that the second half of helix 2 (residues 184–194) 
and parts of helix 3 (residues 200–204 and 215–223) un-
dergo a transition from an α-helical conformation to a β 
and/or random coil state during PrPC to PrPSc conver-
sion79. These results are consistent with recent hydrogen  
exchange (HX), electron paramagnetic resonance (EPR) 
spectroscopy, and solid-state NMR (ssNMR) studies (see 
below). 
 The structure of amyloid fibrils formed by recombinant 
human prion protein (r-huPrP) has been studied in detail. 
They are formed at pH 7, typically in the presence of 2M 
guanidine hydrochloride (GdnHCl), and are shown to be 
infectious in transgenic mouse models over-expressing 
PrPC (ref. 80). HX, site-directed spin labelling and EPR 
spectroscopy have suggested that the core of r-huPrP 
amyloid fibrils is composed of the C-terminal region  
of the protein molecule, which spans helix 2, a major  
part of helix 3, and the loop between these two helices  
in the native structure81,82. No extensive hydrogen bond-
ing, as indicated by the lack of significant protection 
against HX of amide hydrogens, has been detected in the 
N-terminal part of the PrP 90–231 fibrils, arguing against 
the involvement of the N-terminal region in the β-
structure core. Single line spectra observed in the core 
region of PrP using site-directed spin labelling and EPR 
spectroscopy have suggested that these residues form 
monolayers that stack on top of one another, forming a 
parallel in-register β-structure (Figure 2 e)82. ssNMR 
studies of the full length Syrian hamster PrP (shaPrP; 23–
231 residues) amyloid fibril, also suggest that the core of 
mammalian prion amyloid fibrils corresponds to residues 
173–224 (ref. 83), and that the β-sheets are indeed  
arranged in a parallel in-register structure (Figure 2 e). 
Hence, high-resolution data strongly indicate that the 
PrPC to PrPSc conformational transition occurs in the  
C-terminal domain during amyloid fibrillation. 
 The amyloid fibrils formed by many other proteins too, 
including amyloid β 84,85, α-synuclein86, tau87, barstar88 
and yeast PrP (Sup35NM, Ure2, Rnq1)89–91 adopt in-regi-
ster parallel β-sheet conformations, in which the adjacent 
peptide chains line up in the same N to C orientation, 
with corresponding residues apposing each other. It 
seems to be the most common fold of amyloid fibrils. 
 The Y145 stop mutation in huPrP (huPrP 23–144) is 
associated with inherited prion disorders. There have 
been extensive structural studies of the amyloidogenic 
aggregates of this protein variant. Magic angle ssNMR 
spectroscopy has suggested that the core of the amyloid 
fibrils formed by this variant encompasses residues 112–
141 (ref. 92), and that most of the other residues are 
largely disordered. The core is composed mainly of three 
β-strands, containing residues 112–115, 118–122 and 
130–139. Similarly, a study with a moPrP 89–143 vari-
ant, containing the inherited prion disorder-associated 
mutation P101L, has suggested that residues 112–124 
adopt an extended β-sheet conformation93. HX measure-
ments have suggested that the core of fibrils formed by 
this fragment is composed of two β strands, containing 
residues 102–109 and 117–136, joined by a conforma-
tionally heterogeneous turn formed by residues 110–116 
(ref. 94). From these studies, it seems that in the case of 
prion fragments lacking the C-terminal domain, the fibril-
lar core is composed mostly of residues 102–139. But in 
the case of the full-length prion protein, residues 160–220 
form the core of the fibrils, and it remains to be answered 
as to why, despite their propensity to adopt a β-sheet con-
formation, residues 102–139 do not participate in fibrilla-
tion of the full-length protein. 
 The structure of infectious PrPSc remains obscure. 
ssNMR-based studies have been carried out on an infec-
tious sample of yeast PrP91,95, but it is possible that in  
these studies the physical properties of the bulk of the 
amyloid do not represent those of the minority of the in-
fectious amyloids. The structure of an infectious sample 
of mammalian rPrP has also been determined80–82,94,96, but 
the infectivity of this sample was quite low. Importantly, 
it is now possible to generate infectious PrPSc-like con-
formations, whose infectivity is similar to that of PrPSc 
isolated from animals, from rPrP in vitro. This would  
certainly be of great help in understanding the structural 
features of infectious PrPSc. A recent HX study with  
infectious PrPSc has revealed that the core is composed of 
residues 80–90 to 231 (ref. 97). 
 While understanding the structures of amyloid fibrils 
and infectious PrPSc is important, one also needs to  
understand how they form. Also, it is necessary to know 
how the aggregation process gets initiated, what kinds of 
intermediates are formed, and the kinds of residues and 
interactions that are important for their formation. Not 
only will these studies lead to a better elucidation of the 
features of prion diseases, but will also help in the  
generation of therapeutics. 
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Mechanism of amyloid fibril formation 
Amyloid fibril formation seems to commence from par-
tially structured conformations of proteins98–100, which 
appear to provide the necessary intermolecular interac-
tions for assembly. But owing to their transient nature,  
direct structural information on aggregation-competent, 
partially unfolded conformations is available only for a few 
proteins101,102. Partial unfolding in the case of a globular 
protein and partial folding in the case of a natively  
unfolded protein, both leading to the formation of an  
aggregation-competent, partially-structured conformation, 
can be induced by mutations, by changes in the environ-
mental conditions or upon chemical modification103.  
Although a structural perturbation of the native structure 
resulting in the formation of a partially structured con-
formation seems to be necessary, a globular protein could 
conceivably expose a locally unfolded segment, for  
example, during its conformational breathing motions, to 
form amyloid fibrils104. 
 The mechanism of protein aggregation is often  
describable by two basic models, nucleation-dependent 
polymerization (NDP) and isodesmic (linear) poly-
merization105–109. An NDP reaction consists of two stages, 
nucleation and growth. The nucleation phase consists of a 
number of thermodynamically unfavourable equilibria. 
The nucleus represents the highest energy structure, and 
its formation constitutes a bottleneck in the polymeriza-
tion reaction. Once the nucleus is formed, subsequent 
steps become favourable. The kinetics of an NDP reac-
tion107,108 shows a lag phase, which is abolished when a 
small amount of nucleus in the form of fully formed fibril 
is provided as a seed at the beginning of the reaction. 
There is a critical concentration for the formation of a 
polymer, and a strong dependence of the nucleation rate 
on protein concentration. On the other hand, an isodesmic 
(linear) polymerization reaction106 does not involve sepa-
rate nucleation and elongation phases, and polymerization 
from any of the monomeric subunits is equally favour-
able110,111. Each association step involves an identical  
interaction; consequently, the rate constants are inde-
pendent of polymer size. Thus, an isodesmic polymeriza-
tion reaction resembles the elongation phase of an NDP 
reaction. The kinetics of an isodesmic polymerization  
reaction does not involve a lag phase, and no critical con-
centration exists. 
 Kinetic studies can distinguish between the two poly-
merization models, but it is not easy to do so because  
the distinction between them is not always robust, and  
depends on the nucleus size as well as on the associa- 
tion and dissociation rate constants. Furthermore,  
NDP and isodesmic models represent two extremes of 
protein polymerization, and it is conceivable, as seen for 
amyloid fibril formation by several proteins, that a poly-
merization reaction can possess features of both  
models109,111. 
 For a few proteins, the amyloid fibrillation reaction can 
be described well as a NDP reaction. For the aggregation 
reaction of most proteins, however, the kinetics shows 
only weak dependences on protein concentration112–116. 
This weak dependence on protein concentration has been 
interpreted as an NDP mechanism involving a small  
nucleus size. A monomeric nucleus has been suggested in 
the case of polyQ peptides, which indicates that an unfa-
vourable conformational change in the monomeric  
protein may constitute the rate-determining nucleation 
event115,117. An NDP mechanism with a monomeric  
nucleus would be similar to the monomer-directed con-
version model, a model proposed for PrPC to PrPSc con-
version (see below). Furthermore, secondary nucleation 
events, such as nucleation on the surface of pre-existing 
fibrils or on exogenous impurities, have been proposed to 
occur during the formation of amyloid fibrils by a few 
proteins108,112–114,116,118–120. 
 For many proteins, spherical oligomers and/or proto-
fibrils are seen to form rapidly at the beginning of the  
aggregation reaction leading to the formation of mature 
amyloid fibrils. For such proteins, the aggregation 
mechanism has been referred to as ‘assembly via oligo-
meric intermediates’112,121–123. In this mechanism, the 
formation of the pre-fibrillar aggregates appears not to be 
limited by an unfavourable nucleation event, and, there-
fore, can be considered as isodesmic polymerization.  
Because of the heterogeneity inherent in the process, and 
the insoluble nature of mature fibrils, it is not easy to 
carry out kinetic measurements to determine whether the 
pre-fibrillar aggregates are on the direct pathway to mature 
fibrils, or whether they are off-pathway aggregates. For 
example, in the case of yeast prion protein Sup35NM, 
single molecule experiments indicate that fibril growth 
occurs by monomer addition113, which would suggest an 
off-pathway role for the pre-fibrillar aggregates that have 
been reported in other studies112 to be on-pathway.  
Nevertheless, for some proteins, it appears that the pre-
fibrillar aggregates do lie on the direct pathway of fibril 
formation124–129. In such cases, amyloid fibril formation 
might nucleate within the pre-fibrillar aggregates and 
grow via many different ways109. 
 In most amyloid fibril formation reactions, the growth 
of aggregates and the acquisition of β-sheet structure 
seem to be coupled112,121,128,130–132. It appears that the  
associating units (monomers or oligomers) first add on to 
the ends of the growing aggregates, and then undergo the 
β-sheet conformational change. Recently, it has been seen 
for three proteins that amyloid fibril formation occurs 
from conformationally converted oligomeric intermedi-
ates, i.e. the β-sheet conformational change occurs in  
the oligomeric intermediates before they associate with 
the ends of growing aggregates123,127,133. 
 It seems that any individual protein can adopt multiple, 
distinct fibrillar morphologies134, and that a range of pre-
fibrillar states precedes the formation of fibrils by many 
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proteins. In the case of the prion protein, it appears that 
structural heterogeneity prevails at the level of pre-
fibrillar oligomers and protofibrils133. In this context, an 
understanding of the initial and intermediate stages of 
amyloid fibril formation reactions can provide an insight 
into the structural heterogeneity inherent in mature fibrils. 
Understanding the structural as well as the kinetic basis 
of the conformational polymorphism seen in amyloid  
fibril structures is a major goal of studies on protein  
aggregation, including prion protein aggregation studies. 
Prion diseases have several characteristic features not 
shared by other neurodegenerative diseases associated 
with amyloid fibril formation, and it is crucial to gain 
molecular-level insight into how these features arise. 
Characteristic features of prion diseases 
Infectiousness 
The PrPSc conformations can replicate themselves and 
cause the conversion of PrPC to its PrPSc self10,11. The 
ability to be infectious in this manner differentiates prion 
diseases from other amyloidogenic disorders. Prion repli-
cation is often described either by a refolding model 
(monomer-directed conversion; Figure 3 a) or by a seed-
ing model (nucleation-dependent polymerization; Figure 
3 b). According to the refolding model135, PrPC and PrPSc 
are separated by a high activation energy barrier, and the 
conformational change associated with PrPC to PrPSc con-
version constitutes the rate-limiting step for the process. 
 
 
 
 
Figure 3. Models for the conversion of PrPC to PrPSc (an alternative 
conformation). Yellow squares represent PrPC and blue circles PrPSc.  
a, Refolding model and b, Seeding model. Reprinted with permission 
from Weissmann137. 
PrPSc acts as a template and upon interaction induces a 
conformational change in PrPC to convert it into PrPSc. 
According to the seeding model136, PrPSc exist as oli-
gomers, whose formation from PrPC involves a number of 
unfavourable equilibria. PrPSc is therefore regarded as the 
nucleus of a classical nucleation-dependent polymeriza-
tion reaction (see below). Upon formation, PrPSc acts as a 
seed to convert more PrPC into PrPSc, leading to the  
formation of prion fibrils. Because of the presence of an  
unfavourable nucleation step, there is a lag phase in the 
reaction. The exponential nature of the kinetics of this  
reaction suggests that the prion aggregates undergo con-
tinuous fragmentation to generate more and more seeds 
for growth137. Since PrPSc formation is always seen to be 
associated with oligomerization67, the seeding model has 
been widely accepted as the more plausible mechanism 
for the replication of PrPSc. Both models of PrPSc forma-
tion (Figure 3) can be, however, described as slight varia-
tions of the NDP model, where the nucleus is monomeric 
in the case of the refolding model and oligomeric in the 
case of the seeding model. 
Prion strains 
The same prion protein can give rise to a range of infec-
tious conformations (prion strains), which differ in their 
incubation periods, the brain area they affect, and their 
disease phenotypes138–143. Earlier, it was debated whether 
prion diseases occur because of viruses or proteins (see 
above). At that time, the observation of different prion 
strains led to opposition of the ‘protein only hypothesis’, 
because it was difficult to understand as to how a protein 
could adopt multiple conformations. Later, it was shown 
that the prion strains represent distinct conformations of 
PrPSc. These strains show differences in their protease  
digestion patterns144, secondary structure content145, epi-
tope exposure146, as well as stability towards thermal  
denaturation147. When different strains are transmitted to 
isogenic animals, strain differences become apparent as 
differences in incubation periods or phenotypes, suggest-
ing that differences in strains are not because of differ-
ences in the hosts148, but arise from differences in the 
structure of PrP. Strains also appear to differ in glycosy-
lation patterns, and in the attachment of GPI anchors149,150. 
The role of these covalent changes versus non-covalent 
structural changes, in defining the strain is, however, not 
understood143,151. 
Species barrier 
Infectious prion isolated from one species either does not 
transmit or transmits with a longer incubation period, into 
another species. This phenomenon is referred to as the 
‘species barrier’ for prion transmission24. In the case where 
transmission of prion from one species to another occurs 
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with a longer incubation period, subsequent transmission 
to the same species occurs with a decreased incubation 
period. After many rounds of transmission in the same 
species, the incubation period becomes fixed24. This phe-
nomenon is known as adaptation. 
 It now appears that many of the characteristic features 
of prion diseases may originate from the amyloid forma-
tion reaction of the prion protein. It is important to criti-
cally examine the mechanism of mammalian prion protein 
aggregation, the structural heterogeneity inherent in the 
process, as well as the possible roles prion aggregation 
may play in determining the characteristic features of 
prion diseases. 
Recombinant PrP as a model system to study  
prion aggregation 
Recombinant prion protein (rPrP) has been used exten-
sively to study the aggregation of prion proteins. Like 
naturally occurring PrP, rPrP has a folded C-terminal 
domain and an unstructured N-terminal domain, and has 
the disulphide bond linking helices 2 and 3 intact.  
Although it lacks any post-translational modifications,  
including the C-terminal GPI anchor, its structure and 
thermal stability are similar to those of naturally occur-
ring PrP152. This suggests that post-translational modifi-
cations do not affect significantly the stability and 
structure of PrPC. Furthermore, as mentioned earlier, it 
can be converted in vitro into an infectious prion iso-
form43,44. Thus, it becomes an easily producible and  
useful model system to study the conversion of PrPC into 
PrPSc. 
Mechanism of amyloid fibril formation by the  
prion protein 
Onset of prion aggregation 
The observation that amyloid fibrillation reactions com-
mence from partially structured conformations (see above) 
suggests that the process of fibril formation is linked  
intricately with the folding reaction. There have been  
several studies of the folding of the prion protein, mostly 
with fragments (PrP 90–231 or 121–231) containing the 
C-terminal domain, which has a folded structure. The 
prion protein folds rapidly; hence it has been difficult to 
study its folding kinetics and to characterize its folding 
pathway. Early stopped-flow mixing studies of the fold-
ing and unfolding of the C-terminal prion domain 121–
231 had suggested that this domain folds without any  
detectable intermediate153. Later studies showed the pres-
ence of a folding intermediate, as suggested by the devia-
tion from linearity in the folding arm of the chevron plot, 
and a burst-phase change in fluorescence during the reac-
tion154. The folding intermediate was found to be popu-
lated more at acidic pH than at neutral pH154. Continuous-
flow mixing measurements showed that there are two dis-
tinct phases in the folding reaction of the rhuPrP 90–231 
(ref. 155), providing direct evidence for the rapid accu-
mulation of an early folding intermediate (with a time 
constant of 50 μs), followed by a rate-limiting folding 
step (with a time constant of 700 μs)155. The presence of a 
folding intermediate has also been shown by HX studies 
in native-like conditions156. A high-pressure 2D NMR 
study has suggested the presence of a metastable unfold-
ing intermediate at pH 5.2 (ref. 157). 
 It has been suggested that an alternative conformation 
of the prion protein (PrP*) binds to PrPSc and gets con-
verted into PrPSc conformation158,159. The aggregation rate 
shows no direct correlation either with the destabilization 
of the native prion protein or with the familial mutations 
associated with the prion diseases160. Interestingly, the 
familial mutations associated with prion diseases appear 
to stabilize the folding intermediate161, suggesting that 
PrPSc formation might be commencing through this fold-
ing intermediate. Moderate concentrations of denaturants 
stabilize the folding intermediate and facilitate aggrega-
tion154,162. The observation that the intermediate present 
in the folding or unfolding pathway of the prion protein is 
populated more at acidic pH is consistent with the view 
that PrPSc formation can occur in the endocytic pathway 
where the pH is slightly acidic163,164. 
 These indirect lines of evidence suggest that the aggre-
gation of PrP may initiate from the monomeric folding or 
unfolding intermediate. Direct kinetic evidence correlat-
ing the amount of intermediate, when modulated either by 
denaturant concentration or by mutation, with the rate of 
aggregation, is yet to be obtained. 
Equilibrium between α-rich monomer and β-rich  
oligomer 
Native PrP, which is rich in α-helical structure, under-
goes a structural transition into a β-rich conformation in 
the presence of a trace amount of urea with NaCl, or of 
GdnHCl162,165–167. The β-rich conformation has exposed 
hydrophobic surfaces, as indicated by increased ANS 
binding165, and is oligomeric. Its formation involves con-
current protein–protein association and conformational 
change166. The β-rich oligomer appears predominantly 
octameric, as suggested by electrospray mass spectro-
metry measurements168. The native disulphide bond  
remains intact during the oligomerization process166. The 
observation that a partially denaturing condition and 
acidic pH accelerate conversion into β-sheet suggests that 
the unfolding intermediate might be involved in the  
formation of the β-rich oligomer. 
 The pH-dependence of the structural transition sug-
gests that the α-rich monomeric PrP exists in equilibrium 
with the β-rich oligomer168–170. The equilibrium favours 
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the α-rich monomeric PrP at neutral pH, and the β-rich 
oligomer at acidic pH. The β-rich oligomer appears to be 
separated from the α-rich monomeric PrP by a large acti-
vation energetic barrier167. The kinetics of the structural 
transition of the α-rich monomeric PrP into β-rich oligo-
mer is hyperbolic, as monitored by the change in the sec-
ondary structure as well as by the increase in size,  
using size exclusion chromatography166. The reaction 
does not show any effect of seeding, suggesting that this 
process is not autocatalytic, which is characteristic of 
PrPC to PrPSc conversion (see above). 
 Recently, β-rich oligomers have been seen to form at 
pH 2, in the absence of any denaturant128,129,133. At this 
pH, their structure appears to be different from those of 
other β-oligomers reported earlier. Prion oligomers rich 
in β-structures are also formed upon removal of the  
disulphide bond in the presence of NaCl171,172. Further-
more, discrete soluble oligomeric forms are seen to form 
upon thermal unfolding of the prion proteins at low pH 
(~ 3.5) in the presence of salt173–175. 
 Although the far-UV CD spectra of the oligomers 
formed in different conditions suggest that they are β-
rich, they differ in their FTIR spectra173–175. It therefore 
appears that high structural heterogeneity exists in the 
oligomeric aggregates formed by the prion protein. In  
order to understand the phenomenon of prion strains, it is 
crucial to determine the role of structurally distinct prion 
oligomers in the amyloid fibril formation reaction, as 
well as in the pathological diversity of the prion proteins. 
Transition of α-rich monomer into amyloid fibrils 
The α-rich monomer, the predominant form present at 
neutral pH, forms long, straight amyloid fibrils in the 
presence of a denaturant, in a process that appears to be 
nucleation-dependent (pathway I; Figure 4 a and b and 
5)114,168–170. The aggregation kinetics involves a lag phase 
(Figure 4 b), which is abolished upon the addition of a 
small amount of seed at the beginning of the reaction. 
However, the aggregation properties of the prion protein 
are not completely consistent with the classical NDP 
model (see above). Although the kinetics involves an ini-
tial lag phase, the lag phase is only weakly dependent on 
protein concentration, and does not fit to a t2 depend-
ence114 (Jain and Udgaonkar, unpublished). This suggests 
that the aggregation reaction involves secondary nuclea-
tion events114. A plot of the log of the elongation rate  
versus the log of the protein concentration was seen to be 
linear, with a slope of 1, suggesting that the rate-limiting 
step of polymerization is conformational rearrangement 
in the polypeptide upon assembly, rather than associa-
tion114. 
 The length of fibrils depends on pH114; shorter fibrils 
form near neutral pH, where fibrillation is faster, and 
longer fibrils form at lower pH, where the fibrillation  
kinetics is slower. This observation has been interpreted 
in terms of the off-pathway nature of the β-rich oligomer. 
Near neutral pH, a higher amount of monomers leads to 
rapid nucleation. Hence a large number of nuclei are 
formed, leaving behind a small concentration of mono-
mers available for elongation, and, consequently, shorter 
fibrils are formed. At acidic pH, the equilibrium shifts in 
favour of the β-rich oligomer, and due to a smaller con-
centration of the α-rich monomer, fewer nucleation sites 
are formed, leaving behind a relatively larger concentra-
tion of monomers to take part in the elongation of the  
nuclei into fibrils. Consequently, longer fibrils are formed 
at acidic pH. 
 In a recent study (Figure 6), spherical oligomers were 
seen to form during the initial lag phase of the kinetics of 
amyloid fibril formation at neutral pH. Interestingly, 
these oligomers appear to be capable of seeding the  
aggregation reaction, which suggests that they are on the 
direct pathway to the mature fibrils (Jain and Udgaonkar, 
unpublished). The presence of an oligomeric intermediate 
can explain the unusual nature (weak dependence of the 
lag phase as well as of the aggregation rate constant on 
protein concentration) of prion protein aggregation (see 
above). It would be important to characterize the core of 
these oligomers and fibrils in order to gain insights into 
how these oligomers lead to the formation of fibrils. 
 High-resolution atomic force microscopy studies on the 
long, straight amyloid fibrils formed by the full-length 
mouse prion protein (moPrP) have suggested that the  
fibrils are highly heterogeneous in their structures. They 
differ in the number of protofilaments as well as in the 
manner in which the protofilaments are intertwined to 
form fibrils176. Several other studies have also exposed 
the heterogeneity inherent in prion fibril structures. 
Changes in the aggregation conditions have been seen to 
lead to the formation of morphologically distinct prion 
fibrils which differ in their stabilities, as monitored by 
epitope exposure using ELISA at different GdnHCl con-
centrations177. Differences in shaking conditions were 
also found to lead to structurally and morphologically 
distinct fibrils (S-shaped and R-shaped fibrils)178, but it 
seems that a contamination of 0.1–1% PrP 30–231 in the 
full-length PrP 23–231 preparation was responsible for 
these two conformational variants of fibrils179. These two 
fibril polymorphs had different folding patterns of the  
β-strands, as characterized by CD, FTIR, HX, proteinase 
K digestion and the binding of conformation-sensitive 
fluorescence dyes, suggesting that they had different  
secondary, tertiary and quaternary structures180. 
The β-rich oligomer leads to the formation of  
worm-like fibrils 
Many studies had suggested that the β-rich oligomer is an 
off-pathway aggregate and does not directly participate in
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Figure 4. Amyloid fibril formation by the mouse prion protein. a, AFM image of worm-like fibrils formed at pH 2. b, 
Kinetics trace of worm-like fibril formation at pH 2. c, EM image of long, straight fibrils formed at pH 7. d, Kinetic trace 
of long, straight fibril formation at pH 7. 
 
 
the aggregation reaction leading to the formation of long 
straight fibrils by the prion protein. An off-pathway role 
for the β-rich oligomer had been indicated by a study of 
the pH dependence of the formation of long, straight  
fibrils (see above), which showed that the length of  
the lag phase decreases with an increase in the amount of 
the α-rich monomer, and increases with an increase in the 
amount of the β-rich oligomer. This suggested that  
the formation of long, straight fibrils commences from 
the α-rich monomer169. Epitope mapping, proteinase K 
digestion and peptide mapping suggested that the β-rich 
oligomer and long, straight amyloid fibrils have different 
internal structures168. The off-pathway nature of the  
β-rich oligomer is consistent with the dependence of the 
length of the long, straight fibrils on the pH of the reac-
tion (see above). 
 It is important to realize that the studies suggesting an 
off-pathway role for the β-rich oligomer involved the use 
of high concentrations of salts and denaturant168–170, 
which can inhibit the growth of the β-rich oligomer. In 
the presence of a low concentration of salt and in the  
absence of denaturant, the β-rich oligomer, formed by 
moPrP gives rise to worm-like fibrils at pH 2 (Figure 4 c 
and d)128,133, having a fibrillar morphology that is struc-
turally different from that of the long straight fibrils 
formed from the α-rich monomer (pathways II and III; 
Figures 4 a, c and Figure 5). The worm-like fibrils have 
smaller diameters, as determined from their heights on 
AFM mica, and curly morphologies (Figure 4 c). Interest-
ingly, worm-like fibril formation involves a pathway that 
is distinct from that of the long, straight fibril formation. 
The kinetics of worm-like fibril formation is hyperbolic;
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Figure 5. Pathways of amyloid fibril formation by the prion protein. The α-rich monomeric form of the prion protein exists in a pH-
dependent equilibrium with the β-rich oligomer. At pH 7, the equilibrium favours the α-rich monomers, which, in the presence of sub-
denaturing concentrations of denaturant and upon shaking at 37°C, form long, straight amyloid fibrils (pathway I). The transition of the  
α-rich monomer into long, straight fibrils occurs through spherical oligomeric intermediates, and the transition appears to be nucleation-
dependent. The equilibrium between the α-rich monomer and the β-rich oligomer favours the latter at low pH. The β-rich oligomer con-
verts into worm-like fibrils in a process that appears not to be limited by an unfavourable nucleation event. The β-rich oligomer consists of 
two distinct oligomeric sub-populations, the larger oligomer (oligomer L) and the smaller oligomer (oligomer S). Oligomer S appears to be 
an off-pathway aggregate formed in competition with the on-pathway oligomer L. The transition of oligomer L into worm-like fibrils  
occurs through alternative pathways. In one pathway (pathway II), which operates at 120 mM NaCl, the β-sheet conformational conversion 
follows aggregate growth, while in the other (pathway III), which operates at 200 mM NaCl, the β-sheet conformational conversion pre-
cedes aggregate growth. In pathway II, lateral association of the elongated aggregates, which leads to the formation of mature, worm-like 
fibrils, constitutes the final step. In contrast, lateral association and β-sheet conformational conversion occur simultaneously in pathway 
III. The worm-like amyloid fibrils formed in the alternative pathways differ in their structures. 
 
 
no lag phase is seen (Figure 4 d). The kinetics shows a 
weak dependence on protein concentration, and there is 
no apparent critical concentration, suggesting that the 
process is not limited by nucleation. It appears, therefore, 
that the formation of worm-like fibrils follows the 
isodesmic (linear) polymerization mechanism. It remains 
to be investigated whether the morphologically distinct 
fibrils formed on the separate pathways involve the same 
or different core segments of the amino acid sequence. 
 The fibrillation of moPrP and β2-microglobulin shows 
remarkable similarity128,181. For both the proteins, the 
formation of long, straight fibrils commences from mono-
mers in a nucleation-dependent manner, whereas an oli-
gomer forms worm-like fibrils in a process that appears 
not to be limited by an unfavourable nucleation event 
(Figure 5). The aggregation reaction can be switched  
between the two pathways by a change in aggregation con-
ditions181. It remains to be seen whether the fibril formation 
reactions of other proteins also share this feature. 
 The β-rich oligomer has been shown to consist of two 
distinct sub-populations, namely a large oligomer (oli-
gomer L) and a small oligomer (oligomer S), which differ 
not only in their sizes but also in their secondary struc-
tures129. Interestingly oligomer L, and not oligomer S, 
transforms directly into worm-like fibrils (Figure 5)129. 
The transformation of the β-rich oligomer into worm-like 
fibrils occurs in multiple steps128, and via alternative 
pathways133. The worm-like fibrils formed on the alterna-
tive pathways differ in their external dimensions as well 
as in their internal structures133. The reaction can be 
switched between the alternative pathways by carrying 
out the reaction at different salt concentrations (pathways 
II and III; Figure 5). Salts appear to modulate the aggre-
gation mechanism via a direct physical interaction with 
the protein133. 
 Fibril formation by the full-length prion protein  
requires unusual and typically drastic environmental con-
ditions. The formation of long, straight amyloid fibrils 
requires the presence of 1–2 M of GdnHCl, or both 1 M 
GdnHCl and 3 M urea, with 150 mM NaCl (refs 168, 
170, 182), and invariably requires agitation of the solu-
tions. It is now possible to aggregate a mutant variant,  
associated with an inherited prion disorder, at pH 4 in the 
absence of any denaturant, but continuous shaking is  
essential for the induction of aggregation reaction183. The 
formation of worm-like fibrils occurs only at low pH,  
although it does not require agitation. It would appear 
that protonation of critical residues leads to the formation 
of an amyloidogenic conformation by destabilization of 
the native structure. The formation of worm-like fibrils 
would occur at undetectable levels, and slowly, at pH 7, 
because the protonated amyloidogenic conformation 
would be present at very low concentration at this pH. 
The slowness of the aggregation of such protonated amy-
loidogenic conformations may be physiologically rele-
vant, because the prion diseases are late-onset diseases184. 
REVIEW ARTICLE 
 
CURRENT SCIENCE, VOL. 101, NO. 10, 25 NOVEMBER 2011 1321
 
 
Figure 6. Progress of the aggregation reaction leading to the forma-
tion of long, straight fibrils. AFM images of aggregates formed at  
different time-points during the formation of long, straight fibrils by 
the mouse prion protein. The reaction was carried out at 37°C, pH 7, 
and with 750 rpm shaking. For the 26, 45 and 51 h time-points, the pro-
tein was diluted to 0.6 μM before applying onto the mica. In the case of 
the 66, 74 and 130 h time-points, the protein was diluted to 5 μM  
before applying onto the mica. 
 
Molecular origin of the characteristic features of  
prion diseases 
Infectiousness 
The amyloid fibrils formed by yeast as well as by  
mammalian PrP adopt an in-register parallel β-sheet  
(see above). The parallel in-register structure can explain 
the infectious nature of prion proteins; the ends  
of the fibril provide a template guiding the conformation 
of the new monomer joining the fibril to be the  
same as the last monomer already in the fibril185,186.  
Presently, it is not known whether the conversion of PrPC 
to PrPSc by PrPSc is similar to the conversion of the  
soluble proteins into amyloid fibrils by seeds from the  
fibrils. 
Prion strain 
The phenomenon of prion strain, wherein the same prion 
protein forms a range of infectious particles, appears to 
originate from the ability of a prion protein to aggregate 
into structurally distinct amyloid aggregates. Amyloid 
polymorphs of a prion protein may form by distinct  
arrangements of an amyloidogenic segment in different 
amyloid aggregates (packing polymorphism), by partici-
pation of different amyloidogenic segments in different 
amyloid aggregates (segmental polymorphism), or by a 
combination of the former two (combinatorial polymor-
phism)187. From the observation that distinct amyloid  
aggregates of prion can form in vitro, either upon protein 
mutation or upon a change in aggregation conditions, it is 
conceivable that different mutations in the prion protein, 
or fluctuations in the environmental conditions prevailing 
within cells, underlie the phenomenon of prion strains. It 
is insightful to consider the following observations. 
 Recently, it has been shown that prions can evolve in 
cell culture188. A heterogeneous population of brain-
adapted prion, when transferred to cell culture, adapts to 
the cellular environment, and out-competes the original 
brain-adapted prion188. Upon re-inoculation into the brain, 
it is out-competed by the brain-adapted prion188. Similarly, 
in cell culture, a swainsonine inhibitor-resistant prion sub-
strain becomes selected (evolved) in the presence of 
swainsonine inhibitor. The inhibitor-resistant prion sub-
strain, in the absence of the inhibitor, is out-competed by 
an inhibitor-susceptible counterpart188. This suggests that 
the prion protein aggregates or PrPSc are highly heteroge-
neous and, depending on the environmental conditions, 
only a few conformations survive and are transmitted. 
 When amyloid polymorphs formed under different  
aggregation conditions, were inoculated into mice, it was 
observed that the stable amyloid fibrils produce a prion 
strain with a longer incubation period, whereas the more  
labile amyloid fibrils generated a different strain, which 
had a shorter incubation period177. As suggested by in  
vitro prion aggregation studies176,178, these observations 
imply that the conformational inadaptability between 
various types of PrPSc, which appears to constitute the  
basis of prion strains and the species barrier, can origi-
nate also from the environmental conditions that they 
have evolved in. 
Species barrier 
The species barrier may originate from differences in the 
sequence of a few critical regions of the prion proteins 
from different species, which can lead to the formation of 
species-specific conformations of PrPSc. If the prion  
sequences of two species have differences in these critical 
regions, the PrPSc conformation of one would be incom-
patible with the prion sequence of the other, and the PrPSc 
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conformation of one would be incapable of converting 
the PrPC of another species into PrPSc. It is instructive to 
consider the following observations189,190. 
 PrP 23–144 has been used extensively as a model sys-
tem to understand the species barrier as well as the strain 
phenomenon in prion diseases. Using different fragments, 
it was observed that the fragments ending before residue 
139 did not show a propensity for amyloid fibrillation. 
This indicated that residues within the 138–141 segment 
are critical for amyloid fibrillation191. The PrP 23–144 
fragments of huPrP, moPrP and shaPrP have distinct lag 
phases, and show differences in the structures of the amy-
loid fibrils formed. huPrP can be seeded with huPrP or 
moPrP, but not with shaPrP. moPrP can be seeded with 
either of the three, and shaPrP can be seeded only with 
shaPrP. A comparison of the amino acid sequences in the 
critical region 138–141 of the prion proteins from these 
three species shows species-specific differences at posi-
tions 138 and 139. Interestingly, species-specific substi-
tutions of a single amino acid residue in the critical 
region can bypass the species barrier, as judged by seeding 
capability. Furthermore, the sequence-specific seeding 
specificity correlates well with the structural characteristics 
of the amyloid fibrils formed189,190,192. The degree of dis-
similarity in the steric zipper structure seems to deter-
mine the transmission barrier192. Thus, it appears that 
amyloid fibrils of prion proteins of different species rep-
resent different strains, and that the species barrier, as 
well as prion strains, originate from the inability of the 
conformations of different prion sequences to adapt to 
each other in segments critical for amyloid fibril forma-
tion. 
Conclusions 
Studies with purified proteins are now providing insights 
into the mechanism of prion protein aggregation and the 
structures of prion aggregates. The aggregation reaction 
of the prion protein appears to commence from a partially 
structured conformation, and progression towards prion 
fibrils is highly dependent on the aggregation conditions. 
At neutral pH, the prion protein, under strongly destabi-
lizing conditions, transforms into long, straight fibrils 
with sigmoidal kinetics, and the reaction appears to be 
nucleation-dependent. On the other hand, at acidic pH the 
prion protein aggregates, without any requirement of the 
presence of denaturant, to form worm-like fibrils, a fibril 
morphology that is strikingly different from that of the 
long, straight fibrils that form at neutral pH. The forma-
tion of worm-like fibrils follows hyperbolic kinetics and 
appears not be limited by an unfavourable nucleation 
event. Under both conditions, a structurally diverse en-
semble of oligomeric species is populated at the initial 
stages of the reaction, which appears to lead to structur-
ally distinct amyloid fibrils. The observation that struc-
tural heterogeneity exists also at the initial stages of 
fibrillation, suggests that it sets in early during the reac-
tion. The formation of structurally diverse aggregates at 
the initial stages of the reaction suggests that many dif-
ferent precursor states could be utilized for the formation 
of mature prion fibrils. The transitions of distinct precur-
sor states into prion fibrils appear to utilize distinct path-
ways of aggregation. A change in protein sequence or a 
change in the aggregation conditions, may switch the  
reaction between the available alternative pathways, and 
can thereby lead to the formation of structurally distinct 
prion aggregates. 
 Although the exact relationship of in vitro prion aggre-
gation to prion-mediated cell toxicity awaits future studies, 
the principles of prion aggregation, emerging from the in 
vitro studies, appear to provide potentially the molecular 
basis of prion infection, replication, as well as the origin 
of prion strains. It is, however, important to note that 
similar principles underlie the amyloid fibril formation 
reactions of many other proteins. The parallel in-register 
structure, that potentially defines the molecular basis of 
the infectious nature of the prion protein, is the most 
common fold of amyloid fibrils, and amyloid  
fibrils of many other proteins possess this fold. It is  
increasingly becoming evident that structural heterogene-
ity as well as template-assisted conformational changes, 
are characteristics of protein aggregation by many other 
proteins134,193–195, whose aggregates appear infectious in 
cell culture, as well as upon grafting and injection into 
animals188,196–205. It is not clear as to why infectiousness 
is restricted only to the prion protein in nature, and why 
other amyloidogenic proteins do not appear to be infec-
tious. Future studies may clarify whether the infectious 
nature of the prion protein originates from the presence of 
its C-terminal GPI anchor206, which is absent in other 
amyloid-forming proteins. 
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